New Patents v

70% by weight of carbohydrates, 5-12% by weight of amino acids, peptides and/or pro- teinous substances and furthermore water soluble vitamines of the group B and mineral constituents. From said yellowish-white pollen extracts a new fraction was isolated which is, compared with the pollen extracts, enriched in amino acids and/or peptides and/or proteinous substances.

4952410

PHARMACEUTICAL PRODUCTS OF MOXONIDINE AND

HYDROCHLOROTHIAZIDE

Ben Armah, Wolfgang Stenzel, Vera Planitz, Hamburg, Federal Republic Of Germany as- signed to Beiersdorf AG

Pharmaceutical composition containing mox- onidine (4-chloro-6-methoxy 2-methyl-5-(2- imidazolin 2 yl)aminopyrimidine) or its pharmaceutically acceptable salts and hydro- chlorothiazide (6-chloro-3, 4-dihydro-2H-1,2,4 benzothiadiazine-7 sulphonamide- 1,1-dioxide) and, if appropriate, triamterene (2,4,7-triamino 6 phenylpteridine).

4952565

INCLUSION COMPLEX OF IBUPROXAM WITH BETA-

CYCLODEXTRIN, A PROCESS FOR PREPARING THE SAME AND A PHARMACEUTICAL

PREPARATION CONTAINING THE SAME

Janko Zmitek, Jenny Milovac, Zdravko Kopitar, Mirjan Zorz, Boris Rusjakovski, YU 61000 Ljubljana, Yugoslavia

A new inclusion complex of ibuproxam with beta-cyclodextrin is described, which is prepared by adding ibuproxam to a boiling aqueous solu- tion of beta-cyclodextrin, stirring the reaction mixture at the boiling temperature, cooling to a temperature of 0 degrees C. to 5 degrees C. and isolating the title complex. The analgesic, anti- pyretic and antiinflammatory properties of the inclusion complex of ibuproxam with beta-

cyclodextrin are equivalent to those of ibuproxam alone, but owing to its better water- solubility the complex can be more easily for- mulated into pharmaceutical forms.

4952584

9H-PYRIDO(2,B-8)INDOLE 3 CARBOXYLIC ACID ESTER

COMPOUNDS HAVING USEFUL PHARMACEUTICAL ACTIVITY

Mervyn Thompson, Ian T Forbes, Harlow, United Kingdom assigned to Beecham Group p I c

A compound of formula (I) or a pharma- ceutically acceptable salt thereof." See Patent for Chemical Structure (I) wherein: R1 is hydrogen, C1-6 alkyl, phenyl or phenyl CI-4 alkyl wherein the phenyl moiety is optionally substituted by one or more C1-6 alkyl, C1-6 alkoxy, C1-6 alkyl- thio, hydroxy, C2-7 aikanoyl, halo, trifluoromethyl, nitro, amino optionally sub- stituted by one or two C1-6 alkyl groups or by C2-7 alkanoyl, cyano, carbamoyl or carboxy groups; R2, R3 and R4 are independently selec- ted from hydrogen, C 1-6 alkyl, C 1-6 alkoxy, C 1 - 6 alkoxycarbonyl, C 1-6 alkylthio, hydroxy, C2-7 alkanoyl, chloro, fluoro, trifiuoromethyl, nitro, amino optionally substituted by one or two C 1-6 alkyl groups or by C2-7 alkanoyl, cyano, car- bamoyl and carboxy, and phenyl, phenyl C1-4 alkyl or phenyl C 1-4 alkoxy in which any phenyl moiety is optionally substituted by any of these groups; R5 and R6 are independently selected from hydrogen, C1-6 alkyl, C3-7 cycloalkyl, C3- 7 cycloalkyl-Cl-4 alkyl, C2-6 alkenyl, C1-7 alkanoyl, C1-6 alkylsulphonyl, di-(CI-6 alkyi)amino CI-6 alkyl, 3-oxobutyl, 3- hydroxybutyl, phenyl, phenyl CI-4 alkyl, ben- zoyl, phenyl C2-7 alkanoyl or benzenesulphonyl any of which phenyl moieties are optionally sub- stituted by one or two halogen, C1-6 alkyl, C1-6 aikoxy, CF3, amino or carboxy, or R5 and R6 together are C2-6 polymethylene optionally interrupted by oxygen or NR9 wherein R9 is hydrogen or C 1-6 alkyl optionally substituted by hydroxy; R7 is hydrogen, C1-6 alkyl, C3-6 cyclo- alkyl, C3-6 cycloalkyl-Cl-4 alkyl, C2-6 alkenyl or C2-6 alkynyl; and -CO2R8 is a pharma- ceutically acceptable ester group, processes for its preparation and its use for the treatment or prophylaxis of anxiety or depression.

GP 22 2--.N